Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead.

about

The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients.Low Sodium Diet, Vitamin D, or Both for RAASi-Resistant, Residual, Proteinuria in CKD? The ViRTUE Trial Points the Way Forward but Is Not the Last Word.

P2860

Q48301048-9BD06EAB-8420-4AE8-9E92-E816DE887FC5 Q53749313-41A62232-AED2-48E5-9AC6-BCA6C0696BA5

P2860

Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead.

Item

http://www.wikidata.org/entity/Q38777543

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Renin-angiotensin-aldosterone ...... t strategies and a look ahead.

@en

type

Item

label

Renin-angiotensin-aldosterone ...... t strategies and a look ahead.

@en

prefLabel

Renin-angiotensin-aldosterone ...... t strategies and a look ahead.

@en

P1476

Renin-angiotensin-aldosterone ...... t strategies and a look ahead.

@en

P2093

Barbara Bonino

http://www.w3.org/2001/XMLSchema#string

Francesca Cappadona

http://www.w3.org/2001/XMLSchema#string

Francesca Viazzi

http://www.w3.org/2001/XMLSchema#string

P2860

Supramaximal dose of candesartan in proteinuric renal disease

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function

The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Oral renin inhibitors

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

P2888

s11739-016-1435-5

P304

627-635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11739-016-1435-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Pontremoli

P577

2016-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26984204

http://www.w3.org/2001/XMLSchema#string

Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead.

about

P2860

P2860

Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698